Breast Cancer Clinical Trials in Columbus, Ohio
24 recruitingColumbus, Ohio
Showing 1–20 of 24 trials
Recruiting
Phase 1Phase 2
A Study to Evaluate the Safety, Tolerability, Drug Levels, and Preliminary Efficacy of BMS-986507 Combinations in Adult Participants With Advanced Solid Tumors
Breast CancerLung Cancer
Bristol-Myers Squibb416 enrolled63 locationsNCT06618287
Recruiting
Phase 2
I-SPY TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast Cancer
Breast CancerBreast NeoplasmsHER2-negative Breast Cancer+6 more
QuantumLeap Healthcare Collaborative5,000 enrolled42 locationsNCT01042379
Recruiting
Phase 3
Palazestrant in Combination With Ribociclib for the First-line Treatment of ER+/HER2- Advanced Breast Cancer
Breast CancerMetastatic Breast CancerER Positive Breast Cancer+1 more
Olema Pharmaceuticals, Inc.1,000 enrolled35 locationsNCT07085767
Recruiting
Not Applicable
Feasibility Study of CBCT for IGRT in Cancer Patients
Breast CancerLiver CancerHead and Neck Cancers+3 more
Varian, a Siemens Healthineers Company50 enrolled4 locationsNCT06681233
Recruiting
Phase 3
E-Mindfulness Approaches for Living After Breast Cancer
Breast CancerDepression
NRG Oncology402 enrolled277 locationsNCT06748222
Recruiting
Not Applicable
Cognitive Training for Cancer Related Cognitive Impairment in Breast Cancer Survivors
Breast CancerCognitive Impairments
NRG Oncology386 enrolled680 locationsNCT05896189
Recruiting
Phase 3
Evaluating the Addition of Adjuvant Chemotherapy to Ovarian Function Suppression Plus Endocrine Therapy in Premenopausal Patients With pN0-1, ER-Positive/HER2-Negative Breast Cancer and an Oncotype Recurrence Score Less Than or Equal to 25
Breast Cancer
NRG Oncology3,960 enrolled1209 locationsNCT05879926
Recruiting
Phase 1Phase 2
First-in-Human Study of STX-478 as Monotherapy and in Combination With Other Antineoplastic Agents in Participants With Advanced Solid Tumors
Breast CancerSolid Tumors, Adult
Eli Lilly and Company720 enrolled67 locationsNCT05768139
Recruiting
Phase 3
Study of PF-07220060 With Letrozole in Adults With HR-positive HER2-negative Breast Cancer Who Have Not Received Anticancer Treatment for Advanced/Metastatic Disease
Breast Cancer
Pfizer1,020 enrolled518 locationsNCT06760637
Recruiting
Phase 2
Sacituzumab Govitecan +/- Pembrolizumab in Metastatic TNBC
Breast Cancer
Dana-Farber Cancer Institute110 enrolled15 locationsNCT04468061
Recruiting
Phase 2
ATEMPT 2.0: Adjuvant T-DM1 vs TH
Breast CancerHER2-positive Breast Cancer
Dana-Farber Cancer Institute500 enrolled52 locationsNCT04893109
Recruiting
Phase 3
Phase 3 Study of Gedatolisib as First-Line Treatment for Patients With HR-Positive, HER2-Negative Advanced Breast Cancer (VIKTORIA-2)
Breast Cancer
Celcuity Inc674 enrolled203 locationsNCT06757634
Recruiting
Phase 4
Abemaciclib Dose Escalation to Maintain Intensity (ADE-MI)
Breast Cancer
University of Illinois at Chicago50 enrolled3 locationsNCT06169371
Recruiting
Phase 3
Regional Radiotherapy in Biomarker Low-Risk Node Positive and T3N0 Breast Cancer
Breast Cancer
Canadian Cancer Trials Group2,140 enrolled475 locationsNCT03488693
Recruiting
Not Applicable
Inspiratory Muscle Training in Obese Breast Cancer Survivors
Breast CancerCancer SurvivorsObesity
Ohio State University Comprehensive Cancer Center78 enrolled1 locationNCT05193149
Recruiting
Phase 1Phase 2
A Study of MT-4561 in Patients With Various Advanced Solid Tumors
Breast CancerEsophageal CancerGastric Cancer+13 more
Tanabe Pharma America, Inc.27 enrolled6 locationsNCT06943521
Recruiting
Phase 2
A Single Arm Phase II Study of ADjuvant Endocrine Therapy, Pertuzumab, and Trastuzumab for Patients With Anatomic Stage I Hormone Receptor-positive, HER2-positive Breast Cancer
Breast CancerHER2-positive Breast CancerInvasive Carcinoma of the Breast+2 more
Dana-Farber Cancer Institute375 enrolled32 locationsNCT04569747
Recruiting
Phase 2
Peri-Operative Immune Checkpoint Inhibition and Cryoablation in Women With Triple-negative Breast Cancer
Breast Cancer
University of Texas Southwestern Medical Center80 enrolled4 locationsNCT03546686
Recruiting
Phase 2
DNA-guided Second Line Adjuvant Therapy for High Residual Risk, Estrogen Receptor Positive, HER-2 Negative Breast Cancer (DARE)
Breast Cancer
Criterium, Inc.70 enrolled19 locationsNCT04567420
Recruiting
Not Applicable
Pilot Study of a MIND Diet Intervention in Women Undergoing Active Treatment for Breast Cancer
Breast Cancer
Ohio State University Comprehensive Cancer Center43 enrolled1 locationNCT05984888